HiRO and CHA University Bundang Medical Center Partner to Advance Global Clinical Trials
核心洞察
Harvest Integrated Research Organization (搜索) (HiRO) and CHA University Bundang Medical Center (CBMC) have formed a strategic partnership to enhance global clinical trials.
The collaboration aims to streamline clinical trial processes, foster innovation, and drive advancements in healthcare research across phases I-IV.
CBMC will provide insights and support for clinical trials, while HiRO will promote South Korea's clinical research capabilities globally.
Harvest Integrated Research Organization (搜索) (HiRO) has announced a strategic partnership with CHA University Bundang Medical Center (CBMC) in Seoul, South Korea, to provide comprehensive solutions for global biotech and pharmaceutical companies across all phases of clinical trials (Phase I to Phase IV).
The collaboration aims to streamline trial processes, foster innovation, and drive advancements in healthcare research both regionally and globally. The partnership will focus on feasibility assessments, principal investigator selection, and patient recruitment facilitation.
Leveraging Expertise for Clinical Trial Efficiency
Under the memorandum of understanding (MOU), HiRO and CBMC will combine their expertise to optimize clinical trial processes. CBMC, as part of the CHA Medical Group, brings state-of-the-art medical services and research capabilities. HiRO will showcase South Korea's clinical research capabilities, highlighting its facilities, skilled professionals, and research excellence.
Dr. Young-Sang Kim, Director of CHA Global Clinical Trials Center, stated, "Through our partnership with HiRO, we are poised to elevate our clinical research expertise and medical excellence. Drawing on HiRO’s presence across the US, Europe, and the Asia-Pacific region, we are reinforcing our commitment to providing more effective and pioneering treatments on a global scale, ultimately improving outcomes for patients in need."
South Korea as a Prime Destination for Clinical Trials
HiRO's founder and CEO, Dr. Karen Chu, emphasized South Korea's robust healthcare infrastructure and favorable research environment. "South Korea is a prime destination for clinical trials," she noted. "We are confident that this partnership will further enhance our ability to offer capital-efficient and high-quality clinical trial solutions, leading to impactful results and significant advancements in medical breakthroughs."
The organizations are committed to exploring innovative approaches together, marking the beginning of a joint effort to shape the future of clinical research in South Korea and internationally. HiRO offers a full spectrum of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, pharmacovigilance, regulatory affairs, statistics, management of data and projects, and clinical and medical monitoring services.